Adult ADHD Treatment Guidelines

Initial Treatment Recommendations

The American Academy of Pediatrics recommends non-stimulant medications such as atomoxetine, extended-release guanfacine, or extended-release clonidine as first-line treatment for newly diagnosed adults with ADHD when there are concerns about medication specificity, substance abuse potential, or diversion risk 1, 2
Evaluate for substance abuse history before initiating any ADHD medication treatment 2
Consider non-stimulant medications first when there is concern about medication diversion or misuse, patient has history of substance abuse, medication specificity is a concern, or there is comorbid anxiety that might be exacerbated by stimulants 1, 2, 3, 5

Atomoxetine is the most extensively studied non-stimulant for adult ADHD and has no abuse potential, making it suitable for patients with substance abuse concerns 1
Extended-release guanfacine and extended-release clonidine are alpha-2 adrenergic agonists with no abuse potential and are particularly useful when there are concerns about stimulant misuse 1, 2
Bupropion has shown anecdotal benefits in adults with ADHD and may be considered when atomoxetine is not tolerated or ineffective 3, 4

Non-stimulants have demonstrated efficacy but with smaller effect sizes compared to stimulants, with effect sizes of approximately 0.7 for non-stimulants and 1.0 for stimulants 6
When comorbidities are present, treat depression first if it is primary or severe, and consider non-stimulant ADHD medication for mild or secondary depression 3, 4
For anxiety comorbidity, non-stimulants may be preferred initially 5, 4

If non-stimulants are ineffective after adequate trial, consider stimulants with lower abuse potential such as lisdexamfetamine, OROS methylphenidate, or dermal methylphenidate 1, 2
For patients with documented substance abuse history, maintain close monitoring if stimulants are prescribed 3, 4
Periodically reevaluate the need for continued medication and monitor for suicidal ideation, particularly during the first few months of atomoxetine treatment 2